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Formalin-fixed paraffin-embedded (FFPE) tissues are a valuable resource for retrospective
clinical studies. Here, we evaluate the feasibility of (phospho-)proteomics on FFPE lung tissue
regarding protein extraction, quantification, pre-analytics, and sample size. After comparing
protein extraction protocols, we use the best-performing protocol for the acquisition of deep
(phospho-)proteomes from lung squamous cell and adenocarcinoma with >8,000 quantified
proteins and >14,000 phosphosites with a tandem mass tag (TMT) approach. With a
microscaled approach, we quantify 7,000 phosphosites, enabling the analysis of FFPE
biopsies with limited tissue amounts. We also investigate the influence of pre-analytical
variables including fixation time and heat-assisted de-crosslinking on protein extraction
efficiency and proteome coverage. Our improved workflows provide quantitative information
on protein abundance and phosphosite regulation for the most relevant oncogenes, tumor
suppressors, and signaling pathways in lung cancer. Finally, we present general guidelines to
which methods are best suited for different applications, highlighting TMT methods for
comprehensive (phospho-)proteome profiling for focused clinical studies and label-free
methods for large cohorts.
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While genomics has transformed clinical cancer researchand diagnostics, mutational profiles are often complexand require additional molecular methods such as
proteomics for functional and clinical interpretation. Compre-
hensive proteomic profiling requires mass spectrometry, which is
now broadly applied to study the consequences of genetic altera-
tions in cancer on the proteome level and enable us to monitor
changes in oncogenic signal transduction by global phosphopro-
teome profiling1–4. In an ideal scenario, it is the best practice for
proteomic and, in particular, phosphoproteomic analysis to work
with fresh frozen tumor tissues5. However, tumor collections of
fresh frozen specimens are typically limited in overall sample
numbers due to additional costs in sample collection and often
lack comprehensive information on treatment and disease out-
comes due to shorter follow-up times. Therefore, formalin-fixed,
paraffin-embedded (FFPE) specimens from routine diagnostic
laboratories are an attractive resource for retrospective studies
because of their long-term stability and often available informa-
tion on clinical outcomes. FFPE tissues are routinely collected in
clinics for histological, immunohistochemical, and molecular
diagnostics such as DNA and RNA sequencing. Resected tissues or
needle biopsies are fixed with formaldehyde solution via the for-
mation of crosslinks between proteins6. Following fixation, the
samples are embedded in paraffin blocks for easy handling and
long-term storage.
Efficient proteomics techniques have been developed and
evaluated for the reversal of crosslinks and protein extraction from
FFPE tissues7–9. Protein crosslinks are usually reversed by sample
boiling, typically in the presence of primary amine-containing
aqueous buffers, and proteins extracted in the presence of various
detergents, such as sodium dodecyl sulfate (SDS)8,10, sodium
deoxycholate (SDC)11, RapiGest12 or organic solvents like tri-
fluoroethanol (TFE)13,14. In all of these FFPE proteomics work-
flows, extracted proteins are later on digested with trypsin into
peptides that are then analyzed by liquid chromatography-tandem
mass spectrometry (LC-MS/MS). Many pre-analytical variables
have been evaluated and no detrimental effect was found so far on
protein abundance and quality due to storage times of FFPE
specimens for ten or more years13,15.
Nowadays, label-free proteomics methods in which peptides
derived from FFPE samples are directly analyzed in a one sample
per one LC-MS/MS run manner (“single-shot runs”) can provide
quantitative information for between 2000 and 5000
proteins14,16,17 and are well suited for analysis of large clinical
cohorts. An alternative to label-free methods are isotopic labeling
techniques, such as tandem mass tag (TMT) reagents, that allow
to chemically modify peptide samples with up to 16 different
barcodes18 and analyze these samples in a multiplexed manner
per LC-MS/MS experiment. Due to the high level of multi-
plexing, more MS instrument time can be spent on a TMT-
labeled multiplexed sample set, therefore frequently a second
dimension of chromatography separation is used and TMT
samples are pre-fractionated into several unique subfractions
before LC-MS/MS analysis19. This approach has been used
successfully in recent studies to profile FFPE tissues for ovarian
cancer10,13, where over 8,000 proteins have been quantified, and
hepatocellular carcinoma20, with over 5000 quantified proteins.
The highest reported phosphoproteome coverage in FFPE sam-
ples so far was achieved with TMT-based methods, at a coverage
of 8000 phosphopeptides derived from 3000 proteins13. Another
benefit of TMT technology is its isobaric nature, which leads to a
summed increase of peptide abundance across all multiplexed
samples. This lead to the development of the booster channel
approach, where one sample within the plex is loaded with
10–200 fold more peptide material compared to the other sam-
ples. TMT booster channel applications are attractive for
microscaled proteome analysis, as previously shown for primary
cells cultured from pancreatic islet samples21, and single-cell
proteome analysis22.
In this study, we focus on the comparison of the two major
non-small cell lung cancer (NSCLC) subtypes adenocarcinoma
(ADC) and squamous cell carcinoma (SCC) as a clinical use case
to benchmark and further improve methods for high throughput,
micro-scaled, and comprehensive proteome and phosphopro-
teome profiling. The presented techniques allow us to monitor
most of the relevant oncogenes, tumor suppressors, and signaling
pathways in lung cancer on the protein or phosphoprotein level,
at starting amounts as little as provided by transbronchial needle
biopsies. We also provide guidelines on what proteomics/phos-
phoproteomics methods to use for different sample sets and
recommend the use of TMT approaches for comprehensive
(phospho-)proteome profiling for focused clinical studies.
Results
Benchmarking protein extraction protocols for FFPE pro-
teomics. We compared three published protocols for protein
extraction from FFPE samples, which differ in lysis buffer com-
position (different detergents) and subsequent sample cleanup, and
performed proteome analyses from FFPE lung tissue (Fig. 1a). The
first protocol published by Hughes et al.10 (SDS-SP3) uses SDS, a
strong detergent that interferes with LC-MS/MS and needs to be
removed before analysis via paramagnetic beads SP3 (single-pot,
solid phase-enhanced sample preparation) cleanup. The second
protocol (SDC) relies on the weaker SDC detergent that can later be
removed by centrifugation after acidification11. The direct trypsi-
nization (DTR) protocol uses the commercially available RapiGest
detergent which increases the enzymatic activity of trypsin and
therefore does not need to be diluted or removed between samples
lysis and digestion12.
Four replicates of 1 × 10 µm FFPE slices (ca. 150 mm2 tumor
area on average) were processed for each of the three protocols
and 1 µg peptide of each sample was injected for LC-MS/MS
measurements. Over 3000 proteins were identified in single-shot
analyses of the four replicates across all three protocols, with the
majority of proteins identified in both the DTR and SDS-SP3
processed samples (Fig. 1b). Comparison of the coefficient of
variation (CV) of the protein intensities over four replicates per
protocol for the proteins identified across all three protocols
shows that the SDS-SP3 protocol has by far the lowest mean CV
(0.35) compared to DTR (0.77) and SDC (0.69) protocols
(Fig. 1d).
Another important validation parameter was the coverage of
relevant proteins for NSCLC (Supplementary Table 2), e.g.,
immunohistochemical markers, like cytokeratins (KRT5/6/7,
immunohistochemistry (IHC) stainings for ADC/SCC shown in
Supplementary Fig. 1A and B), the differentiation-determinant
transcription factor TTF1 (NKX2-1), or the surfactant protein B
processing aspartic protease Napsin A (NAPSA), and known
signaling proteins like the oncogenic kinase EGFR, and members
of the antioxidant response KEAP1-NRF2 pathway (CUL3). Most
of these relevant proteins were covered with both DTR and SDS-
SP3 protocols, but additional proteins like the KEAP1 targeting
E3-Ligase Cullin-3 (CUL3), the epithelial cell adhesion molecule
(EPCAM), or the protein kinase AKT2 were exclusively found in
SDS-SP3 data. Due to the best overall proteome coverage, lung
cancer-relevant proteome coverage, and highest reproducibility
across four replicates (Fig. 1b–d, Supplementary Data 1), the
SDS-SP3 protocol is the best-performing protocol and was used
for subsequent experiments.
As a first application, the SDS-SP3 protocol was used for label-
free quantification (LFQ) comparison of 30 NSCLC cases (16 ADC
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and 14 SCC, Supplementary Table 1, Supplementary Data 2). Over
300 proteins out of 1728 quantified proteins were found to be
significantly different between the two groups with ADC markers
like KRT7 and SCC markers like KRT5/6 being significantly
upregulated in their respective entity (Supplementary Fig. 2A).
With this dataset, we could confirm several markers on a protein
level that had previously been shown on RNA level23, such as
mucin-5B (MUC5B), a glycoprotein that is secreted in the lung and
Fig. 1 SDS-SP3 protocol performs best in terms of total identified proteins and identified NSCLC disease-related proteins. a Comparison of three
sample preparation protocols for FFPE proteome analysis. Deparaffinized FFPE lung tissues were lysed with different buffers containing either SDS, SDC, or
RapiGest, and detergents were removed before digestion and LC-MS/MS analysis. b Overlap of proteins identified in DTR, SDC, and SDS-SP3 treated
samples with NSCLC-relevant proteins highlighted as quality control. * marks proteins only identified but not quantified in any of the groups (27). c Proteins
identified from a 1 µg single-shot injection from the samples processed with the three protein extraction protocols, the black bar is showing the mean of the
group. Source data are provided as a Source Data file. d Boxplots plots showing the distribution of coefficients of variation (CV) per protein across four
replicates for each protocol with boxplots. The plot depicts the 25th and 75th quartile (box), the median (thick black line), the minimum and maximum
(whiskers, Q1-1.5*IQR, Q3+ 1.5*IQR), and outliers (dots). Source data are provided as a Source Data file.
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is associated with poor prognosis in ADC24, kininogen 1 (KNG1),
and serum transthyretin (TTR), which has been shown to be
associated with poor outcome25. In SCC we could confirm
apolipoprotein 1 (APOA1) which has previously been described
as inversely correlated with the risk of lung cancer26. Interestingly,
the paper by Venugopal et al.23 showed fibrinogen alpha (FGA) to
be overexpressed in ADC, in our dataset, however, it was found
with higher expression levels in SCC. In addition, we were able to
quantify several proteins that might be of interest as potential future
markers for lung ADC, such as mucin-5AC (MUC5AC), another
mucin that has been linked to ALK-positive lung ADC27, or
carcinoembryonic antigen-related cell adhesion molecule 6 (CEA-
CAM6), a glycoprotein that is involved in cell invasion and
metastasis and has been shown to have higher expression levels in
ADC compared to SCC via IHC28.
Cystatin A (CSTA) has previously been shown to have a higher
expression in SCC via IHC29 and might be an interesting
potential candidate for SCC.
A subset of these 30 samples consisting of 5 ADC and 5 SCC
cases with sufficient sample amounts for subsequent TMT
proteomic and phosphoproteomic method comparisons was
selected. When ADC vs. SCC label-free proteome differences
were compared in this subset of 10 samples, over 30 proteins were
significantly upregulated in ADC vs. SCC, among which NSCLC-
relevant proteins such as NAPSA and NQO1, another member
of the Keap1-Nrf2 pathway, were represented (Supplementary
Fig. 2B).
The “match between runs” (MBR) feature of the MaxQuant
platform30 was used to maximize the number of quantified
proteins in the LFQ experiment. To ensure that the majority of
quantified proteins is still identified from MS/MS spectra, we
compared the log2-transformed LFQ intensity distributions of all
quantified proteins to the subset of proteins with MS/MS spectra-
based identifications and those only identified with the MBR
feature (Supplementary Fig. 3A). The vast majority of quantified
proteins was identified via MS/MS spectra (90%) and in this
comparison, the MBR algorithm contributes only a small part of
lower-intensity proteins (10%). This can also be seen in the
individual ADC (Supplementary Fig. 3B) and SCC (Supplemen-
tary Fig. 3C) technical replicates where proteins identified only by
spectral matching tend to have lower LFQ intensities and higher
variability. Scatter plots show two technical replicates for all
quantified proteins, for significantly differentially expressed
proteins, and also for NSCLC markers used as quality controls
in this study (Supplementary Fig. 3B/3C left to right). The average
technical correlation for replicate pairs was 0.995 and 0.994 (p <
0.01) for ADC and SCC, respectively. The average biological
correlation for ADC or SCC tumor within-group comparisons
were 0.888 and 0.917, respectively.
Proteins that fall outside a 95% prediction interval in the
scatterplot of technical ADC or SCC replicates are indicated in
the volcano plots (Supplementary Fig. 2A/2B) with an asterisk
symbol (301 out of 5059 proteins) whereby the variability is
usually higher in proteins with lower abundance. We observe that
none of the NSCLC-relevant proteins fall outside of these
intervals.
Assessment of pre-analytical variables for FFPE proteome
profiling. Tissue samples in the routine pathology labs can have
different lengths of fixation time, ranging from overnight fixation
(~24 h) during the week to over-the-weekend fixation (72 h).
Therefore it is important to investigate the influence of different
fixation times on sample quality. To test this, our cohort of 30
NSCLC cases was used. 18 (10 ADC, 8 SCC) samples from the
cohort had been fixed in formalin for 24 h and 12 (6 ADC, 6 SCC)
samples had been fixed for 72 h. No significant differences in the
number of identified proteins were observed between 24 and 72 h
fixation time (Supplementary Fig. 1C). A moderated t-test com-
paring the protein quantities in the samples that were fixed
overnight to those fixed from Friday to Monday showed only two
proteins significantly upregulated (adjusted p-value < 0.05) in the
24 h samples. One was Clusterin (CLU) and the other one
immunoglobulin heavy constant mu (IGHM), both variable
extracellular proteins that are difficult to quantify (Supplementary
Fig. 1D). This shows that there is no relevant bias in protein
groups detected after 24 or 72 h formalin fixation.
In addition, we investigated the impact of fixation time on the
number of formalin-induced modifications. Formalin-fixation has
been reported to cause several protein modifications such as
dimethylation, formylation, or the addition of a methylol group31,
and the storage of samples at room temperature may also cause
methionine oxidation. A comparison of the number of identified
peptides with each modification in samples that had been fixed
either 24 or 72 h showed no significant time-dependent difference
for any modification tested (Supplementary Fig. 1E). Based on
these results, we can conclude that for the study design for
proteomic analyses of larger clinical FFPE cohorts, fixation time
does not have to be a selection criterion.
Next, we investigated the impact of heat on the efficiency of the
de-crosslinking and the stability of the proteome and phospho-
proteome. To avoid sample processing conditions that would lead
to protein degradation or loss of phosphorylation, we compared
different heat incubation times in a cell culture experiment.
HEK293 cells were either fresh-frozen directly after harvesting,
formalin-fixed immediately on the plate, and then harvested or
first incubated at 4 °C for an hour and then formalin-fixed to
mimic processing delays in the routine pathological lab. All
samples were treated with the same SDS-lysis buffer and
replicates of each type of sample were incubated either 10 min,
30 min, 60 min, or 120 min at 95 °C (Supplementary Fig. 4A),
cleaned up with SP3, digested, and run in single-shot analyses. On
peptide level, the two sample groups treated with formalin (cells
fixed immediately and cells fixed after 1 h) showed an increase in
identifications of up to 20% with increased heat incubation time,
while for fresh-frozen cells the number of identifications
decreased by 20% when incubated 120 min instead of 10 min.
In general, only slightly fewer peptides were identified from the
fixed cells at all time points (Supplementary Fig. 4B).
Equal amounts of each sample (100 µg) were enriched for
phosphopeptides by immobilized metal affinity chromatography
(IMAC) and in all three types of samples, the lowest number of
phosphopeptides was identified after 10 min of cooking at 95 °C.
Identification rates increased up to 50% with the maximum
number of phosphopeptides identified at 60 min, then the rates
decreased again slightly (Supplementary Fig. 4C). Noteworthy,
phosphorylation modifications on proteins are stable enough to
withstand heat incubation times of up to 2 h at 95 °C without any
major abundance losses.
These results suggest that a compromise has to be found between
the maximum number of identified peptides or phosphopeptides
and the workflow has to be tailored to the individual application.
For this study, we chose to keep the heat incubation step at two
hours to maximize protein yield.
In addition, a TMT comparison of five replicates of fresh-
frozen HEK293 cells and five replicates of formalin-fixed
HEK293 cells showed a high correlation between the proteomes
of fresh and formalin-fixed cells (Supplementary Fig. 5A) with
Pearson correlation coefficients of 0.96–0.99 (p < 0.01). The
phosphoproteomes of fresh-frozen and formalin-fixed cells also
showed a good correlation with Pearson correlation coefficients
of 0.7–0.9 (p < 0.01), an expected trend, considering that the
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variability is generally higher on the (phospho-)peptide level
(Supplementary Fig. 5B).
Increased proteome/phosphoproteome coverage with multi-
plexed TMT. TMT multiplexing, combined with prefractionation
of peptide samples prior to LC-MS/MS allows to massively
increase the coverage of proteomics experiments while keeping
the instrument time used for individual tumor samples similar to
classical single-shot label-free experiments. Usually, equal peptide
amounts, here 200 µg per sample, are used for isotope labeling
with isobaric compounds, combined and fractionated into mul-
tiple fractions over a high pH gradient. This separation method is
orthogonal to the reversed-phase separation at acidic pH in the
downstream nanoflow LC system and helps reduce overall sample
complexity in each resulting sample fraction. Similar to pre-
viously developed workflows19, we used 10% of the total peptide
material for the proteome analysis and reserved 90% of the
material for IMAC phosphopeptide enrichment and phospho-
proteome analysis. The resulting fractions were analyzed by LC-
MS/MS and individual samples were quantified using reporter
ions derived from their isotope tags (Fig. 2a).
With this equal loading TMT approach, we were able to
quantify on average 9000 proteins per TMT-plex experiment and
an intersection of 8577 proteins corresponding to 8200 genes
without missing values across two TMT11-plexes from FFPE lung
tissue (Supplementary Data 3). The average measuring time per
individual sample was 6 h. This is an increase of over 6000
proteins compared to the LFQ approach for the same set of
samples. While many proteins relevant to NSCLC (e.g., KRT5/6/
7, NAPSA, EPCAM, EGFR) were identified with both the label-
free and equal loading TMT approach, many additional markers
such as tumor protein p63, another SCC marker (TP63), NKX2-
1, NRF2, KEAP1, and CDKN1A (p21), the cyclin-dependent
kinase (CDK) inhibitor, which is also involved in both the
KEAP1-NRF2 pathway and PI3K-AKT pathway32,33 were only
identified in the TMT dataset (Fig. 2b). The proteins identified in
the equal loading TMT dataset cover almost 10,000 proteins over
six orders of magnitude of summed peptide precursor intensities
whereas the LFQ coverage limit is at about 1800 proteins, leaving
many cancer-related proteins or oncogenes like the tumor
suppressor p53 (TP53), oncogenic kinase BRAF and KEAP1
uncovered (Fig. 2c). Concerning the PI3K-AKT signaling path-
way, which plays an important role in NSCLC, because it is
involved in EGFR receptor tyrosine kinase inhibitor (RTKI)
resistance34, most members of the pathway were quantified in the
equal loading TMT dataset (Fig. 3a).
For the phosphoproteome, over 14,000 phosphosites were
quantified in the equal loading TMT dataset, corresponding to
4400 genes and four orders of magnitude in reporter ion
intensities (Fig. 3b, Supplementary Data 4). The deep phospho-
proteome adds additional information, as some proteins such as
the oncogene Myc were only quantified in the phosphoproteome
(Fig. 3a). In addition to quantifying proteins in their
phosphorylated proteoform that have not been found in the
proteome data, there is additional information on pathway
regulation in the phosphoproteome data, for example, in cases
where phosphosites show abundance differences where the
corresponding proteins do not. A comparison of the log2 SCC/
ADC fold changes of the proteome and phosphoproteome
indicated that several proteins are differentially phosphorylated
between ADC and SCC while the protein expression remains
unchanged (Supplementary Fig. 6A). We then performed a gene
ontology molecular function (GO MF) analysis on these
proteins, which identified two groups, 1) proteins involved in
transcription including the transcription factor FOXO3, or 2)
proteins involved in signal transduction, e.g., SOS1 (Supple-
mentary Fig. 6B). SOS1 has been shown to play a role in tumor
growth in lung ADC35, while FOXO3 acts as a tumor suppressor
by regulating apoptosis36. These results show that the standard
TMT technology can be successfully applied to clinical FFPE
samples, providing relevant information on protein expression
and phosphorylation levels.
Microscaled analysis for biopsy equivalents with a booster
TMT sample. The equal loading TMT approach is well suited for
studies in resected FFPE tissues where the sample amount is not a
concern, such as when multiple 10 µm slices of a 5 × 5 mm2
tumor section are available. To investigate the applicability of the
TMT approach for low sample amounts, such as needle biopsy
FFPE samples, we utilized 20 µg instead of 200 µg aliquots of the
same peptide samples used for the equal loading TMT experi-
ment as “biopsy equivalents”. Protein yield can vary between
samples and 20 µg is an amount that one should be able to reli-
ably extract from a large group of clinical biopsy samples. Eight of
the biopsy equivalents were labeled with TMT (channels 1–8) and
combined with a boosting channel of 2 mg internal standard
(channel 11). To avoid carryover due to isotopic impurities of the
labels, two TMT channels between the samples and 100-fold
more abundant internal standard (channel 9 and 10) were left
empty. The precursor intensity of each peptide in the MS1 scans
is here a sum of the intensities across all samples/TMT channels
(Fig. 4a). The boosting channel helps increase the signal over the
minimal abundance threshold that is necessary to obtain enough
fragment ions to determine the amino acid sequence of TMT-
labeled peptides and enough TMT reporter ions for quantification
in MS2 scans.
We were able to quantify on average 7712 proteins per TMT
plex and over 7000 proteins without missing values with this deep
proteome profiling approach for microscaled TMT samples
(Supplementary Fig. 7A, Supplementary Data 5), covering five
orders of magnitude in precursor intensities and biologically
important proteins such as NAPSA, KRAS or KEAP1. The log2
SCC vs. ADC fold changes of equal loading and microscaled
TMT correlated well with a Pearson correlation coefficient of 0.67
and a p-value below 2.2 × 10−16, which shows that the boosting
channel does not skew intensity ratios in the microscaled
experiment (Fig. 4b). To better understand the quantified protein
networks on a biological level, we performed a single-sample gene
set enrichment analysis (ssGSEA37) with the “hallmarks of
cancer” gene sets38. The hallmark pathway “protein secretion”
was significantly upregulated in ADC samples (Supplementary
Fig. 7B). This is consistent with what is known about lung cancer
biology as lung ADC is believed to develop from club cells and
alveolar epithelial type 2 cells, secretory cells in the bronchial
epithelium39. These cells secrete a mix of proteins and
other molecules to protect the epithelium40,41. The hallmark
“inflammatory response” and several immune system-related
terms are upregulated in SCC samples (Supplementary Fig. 7B).
SCC is generally more associated with smoking. Cigarette smoke
contains free radicals that induce oxidative stress and cell damage,
which in turn cause inflammation42.
While 14,000 phosphosites were quantified among the two
equal loading TMT plexes, 8,800 phosphosites were still
quantified among the two microscaled TMT plexes (Supplemen-
tary Data 6). An overlap of 6000 phosphosites was quantified in
both the TMT equal loading and microscaled experiments.
Among these, phosphorylation events on oncogenes like AKT1,
MET and, mTOR were found. Almost 3000 phosphosites were
quantified in the microscaled TMT experiment only, e.g.,
additional phosphosites on MET or TP63 (Fig. 4c).
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The observed coverage differences between equal loading and
microscaled TMT phosphoproteomes can be attributed to
multiple factors. First, the increased complexity of internal
standard containing microscaled TMT samples coincides with
decreased identifications on protein and phosphosite levels by
9.4% and 16%, respectively (Supplementary Fig. 8A/B). Due to
higher sample amount requirements for the internal standard, a
mix of 20 different NSCLC tumors was generated, which is more
complex than the individual 10 tumors in the equal loading
experiment. Second, in the microscaled TMT experiment, we
Fig. 2 Deep FFPE proteome coverage with TMT11 labeling and two-dimensional liquid chromatography. a TMT multiplexing combined with high pH
offline fractionation allows for deeper LC-MS/MS coverage while spending less measuring time per individual sample. Multiplexed, TMT-labeled peptide
samples are loaded in equal total quantities per TMT-channel and fractionated via two dimensions of liquid chromatography before MS analysis. Increased
MS time requirements per TMT experiment for 28 injections are compensated here by multiplexed analysis of up to 11 samples. b Venn diagram showing
the overlap of quantified proteins from LFQ and equal loading TMT quantification. NSCLC-relevant markers are shown as quality control. Only unique
proteins and no isoforms were counted as quantified proteins. * marks proteins only identified but not quantified with either method (0). c Log10 reporter
ion intensity distribution over all proteins that were quantified in equal loading TMT. The LFQ coverage limit is shown in magenta.
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Fig. 3 Phosphoproteome analysis with equal loading TMT11 provides a comprehensive overview of cancer-relevant pathways. a Most key components
of the PI3K-AKT signaling pathway were covered by equal loading TMT on a global proteome (shown in magenta) and phosphoproteome (shown in
orange) level. PI3K-Akt signaling pathway was adapted from KEGG pathway hsa04151. b Log10 reporter ion intensity distribution over all phosphosites that
were quantified in equal loading TMT. Lung cancer-relevant phosphoproteins are indicated by gene names. A coverage of 15,015 and 15,486 phosphosites
was achieved for the two replicates (overlap of 14,133 phosphosites).
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Fig. 4 Deep proteome coverage even from small sample amounts by using a TMT booster sample. a TMT11 combined with a boosting channel allows for
microscaled deep proteome and phosphoproteome analysis of FFPE samples with low sample amounts (20 µg per sample). b Correlation of log2 fold
changes of equal loading TMT and micoscaled TMT experiments in FFPE lung cancer samples shows similar quantification results (Pearson correlation
coefficient r= 0.67, p < 0.01). NSCLC-relevant proteins are highlighted, all other proteins are shown in blue. Source data are provided as a Source Data file.
c Venn diagram showing the overlap in quantified phosphosites between equal loading TMT and microscaled TMT with highlighted phosphosites on
NSCLC-relevant proteins and oncogenes. * marks phosphosites not quantified with either method (0).
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observed a 10.9% decrease going from identified to quantified
phosphosites, whereas there is only a 0.75% difference in the
equal loading TMT. These dropouts are caused by loss of signal in
the tumor TMT channels, while a signal is still present in the
internal standard TMT channel (100× more input). Third,
comparing the two replicate plexes for each TMT experiment
(px1 and px2 for equal loading TMT and px3 and px4 for
microscaled TMT), the percentage of phosphosites reproducibly
quantified in both plexes is higher in the equal loading TMT
than in the microscaled TMT (85.7% vs 63.5%, Supplementary
Fig. 8A/8B). The 22.2 percentage points difference is likely due to
the higher variability of lower abundant phosphopeptides in
microscaled TMT.
The hydrophobicity index43 for the phosphopeptides quanti-
fied in equal loading and microscaled TMT is distributed very
similarly, both for the total phosphoproteome (Supplementary
Fig. 8C) and the subset of phosphopeptides that were either
uniquely quantified in the equal loading TMT dataset or the
microscaled TMT dataset (Supplementary Fig. 8D, see also Venn
diagram Fig. 4c). This suggests that the two TMT approaches do
not show a bias with respect to the type of phosphopeptides that
are enriched and subsequently quantified, but that the differences
arise merely from the variability that is known from the stochastic
detection of peptides in data-dependent acquisition analysis of
low abundant phosphopeptide samples.
With the microscaled TMT approach with only 20 µg of
peptides from each channel and a boosting channel with 100×
more input material, we could still cover most of the PI3K-Akt
pathway (Supplementary Fig. 9A). Here, more proteins were only
covered in their phosphorylated form than in the equal loading
dataset. Examples are p27 (cyclin-dependent kinase inhibitor 1B,
CDKN1B), FOXO3, mTORC2, and p53. This shows that
phosphopeptide enrichment offers additional information, mostly
about proteins with low abundance, as was shown by Park et al.44.
Comparing the PI3K-Akt pathway coverage on a phospho-
proteome level, both the equal loading and microscaled TMT
approach are able to cover almost the whole pathway, with only
very few pathway members only covered by the equal loading
TMT (Supplementary Fig. 9B).
Similarly, the KEGG pathway for NSCLC (Supplementary
Fig. 10A) and the Ras signaling pathway (Supplementary
Fig. 10B), which regulates cell growth and can activate several
other signaling pathways like the PI3K-Akt pathway or the Raf/
MAPK pathway45, can also be largely covered on a phospho-
proteome level by both the equal loading and microscaled TMT
approach.
To ascertain the reproducibility of the microscaled TMT
approach, we designed five TMT11 plexes out of consecutive 10
µm FFPE slices from eight patients (4 ADC and 4 SCC) so that
the samples were randomly assigned to TMT channels 1–8, then
two channels were left empty to avoid carryover from the internal
standard in channel 11. The sample amounts were again 20 µg for
each patient sample and 100× more material for the internal
standard mix. We then performed deep global proteome and
phosphoproteome analyses as with the miscroscaled TMT
samples. The replicate plexes show an average of 8896 proteins
quantified across all five plexes. We quantified >8100 proteins in
all plexes requiring at least 80% valid values and >6500 proteins
were quantified among all five plexes with no missing values at all
(Supplementary Fig. 11A). The average reporter ion intensities of
all plexes were highly correlated with Pearson correlation
coefficients between 0.93 and 0.96 for both ADC and SCC
samples (p < 0.01, Supplementary Fig. 11B).
On the phosphoproteome level, we were able to quantify 9686
phosphosites on average and in these five TMT plexes a
reasonable coverage of almost 4000 quantified phosphosites
across 80% of all tumor samples can be achieved (Supplementary
Fig. 11C). The average reporter ion intensities still showed a good
correlation between all five plexes both for ADC and SCC
samples (p > 0.01, Supplementary Fig. 11D).
It has been shown before that one limitation of the TMT
quantification method is the rising number of missing values
when integrating more and more plexes. This effect is already
seen on the protein level but is even stronger on peptide level46.
A clear advantage of the microscaled TMT approached
presented here is that it provides in-depth coverage on proteome
and phosphoproteome levels but can tolerate much lower input,
hereby enabling comprehensive proteomic characterization of
very small clinical specimens such as needle core biopsies. Our
reproducibility analysis across five microscaled TMT experiments
showed a high degree of reproducibility and only minor losses in
proteome coverage across plexes.
Applying microscaled TMT profiling to clinical FFPE biopsies.
To test the microscaled approach on clinical FFPE needle biop-
sies, an independent set of eight FFPE needle biopsies consisting
of four ADC and four SCC cases was processed with the SDS-SP3
protocol. We could extract, on average, 79 µg of protein material
per biopsy. As with the biopsy equivalents before, we labeled 20
µg per biopsy sample with TMT and added a 100× booster
channel of a reference mix of ADC and SCC samples. In this
experiment, 6800 proteins were quantified from eight FFPE
needle biopsies with no missing values, excluding those only
found in the boosting channel. The quantifications cover summed
up reporter ion intensities of 5 orders of magnitude, including
NSCLC-relevant proteins such as KEAP1, NKX2-1, and ERBB2
(Fig. 5a).
For the phosphoproteome, 90% of the TMT-labeled peptide
material were used and we could reach a coverage of 5200
quantified phosphopeptides (Fig. 5b, Supplementary Data 7),
which is a significant improvement from up to 2000 identified
phosphopeptides in label-free single-shot LC-MS/MS analyses of
FFPE lung needle biopsies (Supplementary Fig. 12A).
Overall, similar numbers of proteins were quantified in TMT
experiments of biopsies and biopsy equivalents (7137 vs. 6792)
with an overlap of 78% (Fig. 5c). This overlap is very satisfying
since some variation between patients is to be expected. On the
phosphoproteome level, fewer phosphosites were quantified in
the TMT biopsy experiments than in the biopsy equivalents (5243
vs. 8798), which could be due to the slightly different cellular
composition of biopsies and resected tissue samples (Fig. 5d,
Supplementary Data 8).
FFPE proteome/phosphoproteome coverage for LFQ and TMT
methods. Protein yields differ for different NSCLC FFPE tissue
sample types, where one 10 µm slice of a resected tissue FFPE
sample with a tumor area of ~150 mm2 yields 150 µg protein on
average and a needle biopsy FFPE sample with a tumor area of
<5 mm2 yields 70 µg protein (calculated from 3 × 10 µm slices). A
proteome quantification coverage of 4400 proteins for FFPE
resected tissues and 2000 proteins for FFPE biopsies can be
expected from one standard LFQ LC-MS/MS run with 1 µg
digested peptide injected (Supplementary Fig. 12B). From 100 µg
peptide input material, around 6300 phosphosites could be
identified in a label-free experiment from resected tissue and
~1700 phosphosites on average from biopsies. This coverage,
combined with the comparatively short hands-on time required
for the preparation of LFQ samples, makes this technique well
suited for high-throughput studies of large cohorts. For a deeper,
more comprehensive coverage, which is particularly relevant for
integrative studies combining proteomic data with genomic data,
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Fig. 5 Deep proteome and phosphoproteome from FFPE needle biopsies. a Log10 reporter ion intensity distribution over all proteins that were quantified
in TMT biopsies. Source data are provided as a Source Data file. b Log10 reporter ion intensity distribution over all phosphosites that were quantified in
TMT biopsies. Source data are provided as a Source Data file. c Venn diagram showing the overlap of quantified proteins between microscaled TMT and
TMT biopsies. Only unique proteins and no isoforms were counted as quantified proteins. * marks proteins not quantified with either method (0). d Venn
diagram showing the overlap of quantified phosphosites between microscaled TMT and TMT biopsies. * marks phosphosites not quantified with either
method (0).
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a multiplexed TMT approach is more suitable. By investing more
efforts in sample preparation with labeling and offline fractio-
nation, and instrument time, 8000 quantified proteins and over
14,000 quantified phosphosites can be reached with an equal
loading TMT experiment for resected FFPE tissues. A micro-
scaled TMT approach can boost the signal for FFPE needle
biopsies to reach 6800 quantified proteins and 5200 quantified
phosphosites (Supplementary Fig. 12B).
Discussion
In the past, FFPE samples have been successfully used for several
label-free proteomics studies in different types of thyroid cancer47,
fetal brain tissue48, Alzheimer’s disease brain tissue49, colon
carcinoma9, uterine tissue50, and lung tumors17,51,52. In our study,
we show that the SDS-SP3 protocol performs best for protein
extraction from lung cancer FFPE samples among three tested
protocols. A similar comparison of FFPE sample preparation pro-
tocols has recently also been published by Griesser et al.53 for laser-
capture microdissected brain tissue FFPE samples, in which the
SDS-SP3 protocol also provided the best results in terms of protein
yield and proteome coverage. This indicates that the SDS-SP3
protocol has a wide range of possible applications across different
laboratories and applications.
We applied the SDS-SP3 protocol to investigate the influence
of pre-analytical variables both during routine pathology lab
processing and proteomics sample preparation and found that
commonly occurring formalin fixation time differences do not
have a significant impact on the lung cancer proteome. An earlier
report by Sprung et al.7 also investigated the effect of different
fixation times of one, two, and four days on the proteome cov-
erage of colon adenocarcinoma FFPE samples. At a coverage of
fewer than 500 proteins across all samples, the authors reported
detrimental effects only after four days of fixation. Our study
covers 24 and 72 h time intervals of fixation as they are frequently
used for routine pathology lab samples and we found no detri-
mental effects on proteome coverage under these tested condi-
tions. Regarding the length of incubation at 95 °C during lysis, a
compromise has to be found between longer cooking time for
increased protein decrosslinking and, therefore, proteome cov-
erage and shorter cooking times for increased phosphoproteome
coverage. In general, both proteins and phosphoproteins appear
to be chemically quite heat-stable in FFPE samples.
Direct comparison of proteomes from fresh frozen vs.
formalin-fixed specimens revealed no major difference in protein
identifications7,54 and minor or no effects on phosphoproteome
quality for mouse liver tissues11,54. Our cell line experiments with
freshly prepared formalin-fixed cells also revealed only minor
differences in the proteome and phosphoproteome coverage
compared to fresh frozen material. In contrast, a recent qualita-
tive comparison of phosphoproteome coverage for fresh frozen
vs. FFPE ovarian cancer specimens in long-term archived FFPE
tumor specimens revealed a 75% lower identification rate of
phosphopeptides, with the best reported FFPE tissue phospho-
proteome coverage so far of 8000 phosphopeptides derived from
3000 proteins13. The improved protocols we report here, allow
now to further improve the phosphoproteome coverage from
FFPE cancer tissues to >14,000 phosphosites on 4400 proteins.
This increase in coverage can be in part attributed to an auto-
mated IMAC enrichment on AssayMap tips that requires no
desalting of the enriched phosphopeptides after elution from the
IMAC resin, reducing overall sample losses. Particular caution
needs to be applied to the interpretation of FFPE phosphopro-
teome data, since cold ischemia effects before complete fixation of
the tissues may lead to activation of stress response pathways to
some degree in the tissues5. Still, FFPE phosphoproteome
profiling can deliver valuable information by adding information
on the phosphorylation status of proteins that were also detected
in proteome profiles, by extending the overall list of detectable
gene products by a class of proteins that were not covered in the
corresponding proteome datasets and also by revealing activation
events on proteins that show differential regulation across disease
states only on the phosphorylation but not on the individual
protein level. In our study, this was especially the case in the
microscaled TMT approaches, where oncogenes and tumor
suppressors such as Myc, FOXO3, and p53 were only quantified
on the phosphoproteome level.
Our systematic comparison of commonly used FFPE protein
extraction protocols, proteomics quantification methods, and
input amount requirements on different FFPE sample types
allows us to frame general guidelines for FFPE proteome analyses:
LFQ requires only low amounts of input material for proteome
analysis, relatively short sample preparation time and the least
amount of measuring time per sample on the mass spectrometer
(Fig. 6a). Therefore, LFQ is particularly well suited to study large
cohorts of several hundred samples at moderate coverage. How-
ever, for phosphoproteome profiling, the approach is limited due
to its relatively high starting amount requirements per individual
sample. The equal loading TMT approach offers proteome and
phosphoproteome at a much deeper coverage, but requires a
relatively high starting amount of material and substantially more
sample preparation time considering the additional sample pro-
cessing steps for labeling, fractionation, and desalting. A clear
advantage of the microscaled TMT approached presented here is
that it provides in-depth coverage on proteome and phospho-
proteome levels but can tolerate much lower input, hereby
enabling comprehensive proteomic characterization of very small
clinical specimens such as needle core biopsies (Fig. 6b).
Our reproducibility analysis across five microscaled TMT
experiments showed a high degree of reproducibility and only
minor losses in proteome coverage across plexes. Due to missing
value propagation for low input samples across TMT cassettes, we
recommend using the microscaled phosphoproteome approach
only for up to four plexes, with up to 64 samples in TMT16-
mode, until better methods with improved reporter ion sensitivity
are developed. Previous cancer studies with 45 medulloblastoma
cases55, 27 breast cancer tumors56 or 38 prostate cancer samples57
and drug response profiling studies with 48 Jak2-mutated
neoplasms58 show that these cohort sizes can already be useful
to molecularly characterize cancer subtypes and help in the dis-
covery of future biomarkers.
Another label-free mass spectrometry approach for the analysis
of large retrospective clinical cohorts, that was not explored in
this study however, are data-independent acquisition (DIA)
methods that were recently applied to quantify ~5000 proteins
per sample from several FFPE tissues14.
To conclude, our results show that that the commonly used
quantification methods in mass spectrometry-driven proteomics,
LFQ and TMT, both have different strengths and weaknesses for
the analysis of FFPE tissues and offer versatile technological
options to explore the consequences of genetic alterations in
cancer on a functional proteome level.
Methods
Study design. For the protein extraction protocol comparison, four replicates of
FFPE lung ADC tissue samples containing one 10 µm scroll (ca. 150 mm2 tumor
area on average) each were used per protocol.
For the heat incubation time comparison, four replicates per time point were
used for all three sample types (fresh-frozen cells, immediately formalin-fixed cells,
and cells formalin-fixed after 1 h at 4 °C). The cells harvested from one T75 flask
were used per replicate.
For the deep proteome and phosphoproteome analysis of ADC and SCC FFPE
tissues, six 10 µm scrolls (ca. 150 mm2 tumor area on average) were combined per
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Fig. 6 Guidelines for LFQ, equal loading TMT, and microscaled TMT proteome/phosphoproteome analysis in different settings. a A spider plot
showing the strengths and weaknesses of the three quantification methods presented in this study (LFQ in blue, equal loading TMT in magenta, and
microscaled TMT in orange). From the inside to the outside the nodes represent quantities for the proteome between 1000 and 8000 proteins, for the
phosphoproteome between 1000 and 14,000 phosphosites, for the mass spectrometry measuring time 7 and 1 h, for the low input material between 200
and 20 µg of total protein, and for the sample preparation time 50–10 h in the laboratory. For detailed values see supplementary Fig. 12B. b Flowchart for
choosing a suitable quantification method for retrospective FFPE studies depending on the desired throughput and available sample amount. *Equal loading
and microscaled TMT proteome analyses are recommended for 20–200 samples, microscaled TMT phosphoproteome analysis is recommended for
20–50 samples.
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sample. From those, 200 µg peptide was used per sample for the equal loading
TMT and 20 µg peptide per sample was used as “biopsy equivalents” for the
microscaled TMT experiment.
Only for one out of the ten samples, the FFPE biopsy had enough material left
after routine molecular pathology analyses to be included in the TMT biopsy
experiment. Therefore seven additional FFPE needle biopsy samples from the
archives were used for the TMT biopsy experiment. Three 10 µm slices (~5 mm2
tumor area on average) were combined per biopsy sample.
FFPE NSCLC samples were acquired from the archive of the Institute of
Pathology of the Charité University Hospital Berlin, Germany. Informed consent
was obtained from all patients through the patient contract in accordance with
institutional guidelines approved by the ethics board at the Charité
Universitätsmedizin Berlin.
Immunohistochemical staining. Immunohistochemical (IHC) staining was per-
formed on the BenchMark XT (Ventana) automated slide stainer for cytokeratins
5/6 (clone EP24, EP67 (abcam), diluted 1:100) and cytokeratin 7 (clone OV-TL12/
30 (Dako), diluted 1:1000) according to the manufacturer’s instructions.
Deparaffinization. For the resected tissue samples, 10 µm scrolls (ca. 150 mm2
average tumor area) of lung FFPE tissues that had been routinely fixed in 4%
buffered formalin were deparaffinized by three incubations with 1 mL xylene. After
brief vortexing, the samples were centrifuged at 12,700 × g for 10 min and the
supernatant was discarded. The samples were rehydrated afterwards by incubation
with 1 mL 100%, 80%, and 70% ethanol, followed by an air-dry step for 10 min
under a fume hood and stored at −80 °C until use.
For the FFPE biopsies, 10 µm slices (5 mm2 tumor area on average) were
mounted on microscope slides, incubated at 70 °C for 10 min to melt the paraffin,
and cooled down to room temperature. Afterwards, the glass slides were incubated
in xylene for 10 min, briefly air-dried, and then incubated in 100% ethanol for
10 min. The tumor area that had been marked by a pathologist before was then
scraped off and transferred into a 1.5 mL tube using 50% ethanol. The samples
were then centrifuged at 12,700 × g for 10 min, the ethanol was removed, and the
samples were air-dried.
Cell culture. HEK293 cells were cultivated in 1% DMEM with 10% FCS and 1%
penicillin-streptomycin. The cells were processed once they reached about 90%
confluency.
After removal of medium and two washing steps with cold PBS, four T75 flasks
of cells were fixed directly with formalin for three hours at room temperature.
Afterwards, they were again washed with PBS and harvested.
Another four flasks were left in PBS at 4 °C for 1 h, then PBS was removed, they
were fixed with formalin for 3 h and afterwards again washed with PBS and
harvested.
A third batch was harvested and frozen directly.
Direct trypsinization protocol (DTR). The samples were processed according to
the protocol by Föll et al.12. Briefly, deparaffinized FFPE tissues were incubated
with 100 µL buffer containing 0.1% Rapigest, 0.09 M HEPES, pH 8,0, 0.2 mM
DTT in LC-MS grade water for 2 h at 95 °C in a thermoshaker. Afterwards, the
samples were treated with a Bioruptor Pico sonicator (20 cycles on high, 30 s on/
off) and centrifuged for 10 min at 12,700 × g. An aliquot of the supernatant was
used for protein level BCA. After reduction and alkylation with 5 mM DTT and
15 mM IAA, the samples were pre-digested with trypsin and endopeptidase C
(LysC) (enzyme:substrate ratio 1:50) for 2 h at 50 °C. The samples were then
cooled to room temperature and incubated at 37 °C with fresh trypsin and LysC
(enzyme:substrate ratio 1:50) overnight. The digested peptides were acidified
with 100% formic acid the next morning, insoluble particles were spun down,
and the peptides were desalted on C18 material. An aliquot of the desalted
peptides was used for a peptide level BCA.
Sodium deoxycholate-based protocol (SDC). The SDC protocol was first
described by Wakabayashi et al.11. The deparaffinized tissues were incubated with
80 µL buffer containing 2% SDC and 1mM EDTA in 50 mM Tris in a thermo-
shaker for 2 h at 95 °C, treated with a Bioruptor Pico sonicator (20 cycles on high,
30 s on/off), and centrifuged for 10 min at 127,000 × g. An aliquot of the super-
natant was used for protein level BCA. Samples were reduced and alkylated with
12.5 mM DTT and 55 mM IAA and then diluted 1:5 with Tris and then pre-
digested with LysC at 25 °C and digested overnight with trypsin at 37 °C (enzyme:
substrate ratio 1:50). After digestion, ethyl acetate was used to remove the
remaining paraffin, and the samples were acidified with 100% formic acid. Inso-
luble particles were spun down and the peptides were desalted on C18 material. An
aliquot of the desalted peptides was used for a peptide level BCA.
Sodium dodecyl sulfate-based protocol (SDS-SP3). The protocol was first
described by Hughes et al.10. Here, the deparaffinized tissues were incubated with
40 µL buffer containing 50 mM Tris, 1% SDS, and 2 µL benzonase for 30 min at 37
°C. Afterwards, 40 µL buffer containing 2% SDS and 5mM DTT were added and
the samples were incubated for 2 h at 95 °C, treated with a Bioruptor Pico sonicator
(20 cycles on high, 30 s on/off) and centrifuged for 10 min at 127,000 × g. An
aliquot of the supernatant was used for protein level BCA. After alkylation with
50 mM IAA, the remaining IAA was blocked with 113 mM DTT. 10 µL mix of
paramagnetic beads containing 1:1 hydrophilic and hydrophobic beads were added
for a concentration of 1 µg protein:10 µg beads. The concentration of organic
solvent was increased to >70% by the addition of 800 µL acetonitrile and the
proteins were incubated with the beads first on the bench and then in the magnetic
rack. After the beads had settled, the supernatant was removed, and the beads were
washed three times with 70% ethanol. Proteins were eluted from the beads with
100 µL 50 mM HEPES, pH 8. Digestion was performed overnight with LysC and
trypsin (enzyme:substrate ratio 1:50). The next morning, samples were again
incubated on the magnetic rack and the bead-free supernatant was transferred to
fresh tubes and the beads were washed again with 100 µL HEPES. Samples were
acidified with 100% formic acid, and desalted on C18 material. An aliquot of the
desalted peptides was used for a peptide level BCA.
TMT labeling and fractionation. Dried down peptides (200 µg for equal loading
TMT and 20 µg for the microscaled experiments) were reconstituted in 25 µL
50 mM HEPES, pH 8 for the patient samples selected for the deep multiplexed
proteome analysis. The remaining 18 samples were combined in equal amounts for
an internal standard, of which 200 µg were used for the equal loading TMT
experiment and 2000 µg for the microscaled TMT experiments with biopsy
equivalents and actual needles biopsies. The samples and the internal standard
were labeled with TMT reagent with a reagent:peptide ratio of 1:1 for 1 h, then the
reaction was quenched with 1 µL 1M Tris for 15 min and the samples were mixed,
dried down, and subsequently desalted on C18 material.
High pH reverse phase (hpH) fractionation of the labeled samples was
performed on an Agilent 1290 system, as described by Mertins et al.19. Here, the
samples were separated over a 96 min gradient with increasing acetonitrile
concentration ranging from 2 to 54% acetonitrile with 2.5% ammonium formate.
The samples were initially separated into 96 fractions, of which every 28th
fraction was then combined for the global proteome analysis. Ten percent of these
28 fractions were dried down and used for global proteome analysis. The remaining
90% were further combined into ten fractions for phosphoproteome analysis.
Phosphopeptide enrichment. Phosphopeptide enrichment was performed on an
Agilent Bravo automated liquid handling platform using Fe(III)-NTA cartridges.
Hundred micrograms of peptide were used as input material for the cooking time
comparison and duplicates of 100 µg TMT-labeled and hpH-fractionated peptide
were enriched and subsequently combined for the deep phosphoproteome analysis.
Mass spectrometry data acquisition. Data acquisition for LFQ comparison of
ADC and SCC, as well as all TMT experiments, was performed on a Q Exactive
HF-X instrument (Thermo Scientific, Xcalibur software version 4.1.31.9) coupled
to an easy nLC 1200 system (Thermo Scientific). For the cooking time comparison,
a Q Exactive Plus instrument (Thermo Scientific, Xcalibur software version 3.0.63)
with an easy nLC 1200 system was used. The peptides were separated over a
110 min gradient with a flow rate of 250 nL with increasing concentration of buffer
B (up to 60%) on a 20 cm reversed-phase column packed in-house with 1.9 µm
beads (ReproSil Pur, Dr. Maisch GmbH).
The Q Exactive Plus was operated in data-dependent mode with 70 K MS1
resolution, AGC target of 3 × 106 ions, and a maximum injection time of 50 ms,
choosing the top 20 ions for MS2 scans with 17.5 K resolution, AGC target of 5 ×
104 ions and maximum injection time of 250 ms.
The Q Exactive HF-X was set up for 60 K MS1 resolution with an AGC target of
3 × 106 ions and maximum injection time of 10 ms, followed by 20 MS2 scans with
45 K resolution, AGC target of 1 × 105 ions, and maximum injection time of 86 ms.
Data analysis. Database searches were performed using MaxQuant (v1.6.3.3)59
and the human reference proteome (UP000005640, downloaded 01/2019). Oxi-
dation (M) and acetylation (N-term) were always included in the search as variable
modifications, as well as carbamidomethyl cysteine as a fixed modification.
For the label-free comparison of 30 NSCLC cases, the integrated LFQ
calculation was activated and the “match between runs” feature was used, as well as
for the single-shot phosphopeptide-enriched samples, while it was turned off for
protocol comparison and heat-incubation comparison. For TMT analyses, MS2
based labeling was chosen and the correction factor for each channel was entered
according to the manufacturer’s information. Reporter PIF was set to 0.5. For
phosphoproteome analyses, phosphorylation (STY) was included as an additional
variable modification.
Variable modification settings for FFPE samples. Resected tissues or tissue
biopsies are fixed in a solution of 3.7% formaldehyde in water with methanol as a
stabilizer, where they are dehydrated and stabilized by the formation of crosslinks
between proteins6. Here, the formaldehyde reacts with primary amino groups of
the proteins, which are then dehydrated and, in turn, react with amino acid resi-
dues within the protein itself or in other proteins31. After protein extraction and
enzymatic digestion, both peptides that have been extracted and digested
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completely and peptides that still contain the formaldehyde-induced modifications
will likely be found, increasing the sample complexity and interfering with the
confident peptide and protein identification60,61. N-terminal formylation11, lysine
methylation45, and methionine oxidation62 have been reported, among others.
Besides the standard MaxQuant settings for label-free analyses, formylation, the
addition of a methylol group (–CH2O), and dimethylation (KR) were set as
additional modifications.
Filtering of protein identifications and statistical analysis. Proteins that were
flagged as potential contaminants by MaxQuant were not removed during the
analysis later on since three human cytokeratins are used as immunohistochemical
markers for ADC and SCC. Reverse hits and proteins only identified by site were
removed.
The limma R package63 was used to perform two-sided moderated t-tests for
the comparison of ADC and SCC in the different experiments. Multiple testing
correction was performed via the Benjamini-Hochberg procedure and only hits
with an adjusted p-value < 0.05 were considered statistically significant.
For the label-free proteome analyses of 30 FFPE samples, 16 ADC and 14 SCC
samples were compared with two replicates each with a moderated t-test. The
resulting -log10 of the adjusted p-values was then plotted over the log2 fold change
between ADC and SCC in volcano plots. Proteins with a Benjamini-Hochberg-
adjusted p-value < 0.05 were marked as statistically significant hits. The subset of 5
ADC and 5 SCC samples was analyzed in the same way.
Gene set enrichment analysis was performed with the ssGSEA and PTM-SEA
tool for proteome and phosphoproteome analysis, respectively37.
GO term enrichment was performed using the clusterProfiler R package64 and
only hits with Benjamini-Hochberg-adjusted p-values < 0.05 were considered
statistically significant.
Pearson correlations were calculated and plotted using the corrplot R package65.
KEGG pathway plots were rendered with the Pathview R package66.
Potential blood contamination quality control in needle biopsies. Needle
biopsies are taken during bronchoscopy or CT-guided procedures without the
possibility to limit blood flow to the target tissue. Therefore the biopsies often
contain more blood than resected tissue FFPE samples. This is not an issue for
DNA analyses, since erythrocytes do not contain DNA, but they do contain pro-
teins which in high abundance could influence the identification and quantification
of tumor proteins. To investigate the difference in blood content in biopsies and
biopsy equivalents, we used a list of 276 proteins identified in dried blood spots by
Chambers et al.67 as a reference. In the biopsy equivalents (derived from resection
specimens), 199 proteins out of 276 were identified and 181 out of 276 were
identified in the needle biopsies. The intensity distributions of blood proteins in
both experiments behave very similarly to the majority of the proteins showing a
summed-up intensity between 1010 and 1011 (Supplementary Fig. 13). Substantial
differences between the proteomes of FFPE resected tissues and needle biopsies due
to blood contamination can, therefore, be excluded.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Mass spectrometry raw files and processed MaxQuant datasets are available on the
PRIDE proteomics data with the accession code PXD024800. Source data are provided
with this paper.
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